Cargando…

Genetic background influences the 5XFAD Alzheimer’s disease mouse model brain proteome

Mostrar otras versiones (1)

There is a pressing need to improve the translational validity of Alzheimer’s disease (AD) mouse models. Introducing genetic background diversity in AD mouse models has been proposed as a way to increase validity and enable discovery of previously uncharacterized genetic contributions to AD suscepti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurst, Cheyenne D., Dunn, Amy R., Dammer, Eric B., Duong, Duc M., Seyfried, Nicholas T., Kaczorowski, Catherine C., Johnson, Erik C. B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312637/ https://www.ncbi.nlm.nih.gov/pubmed/37398142 http://dx.doi.org/10.1101/2023.06.12.544646

Ejemplares similares

Genetic background influences the 5XFAD Alzheimer's disease mouse model brain proteome
por: Hurst, Cheyenne D., et al.
Publicado: (2023)

Integrated Proteomics to Understand the Role of Neuritin (NRN1) as a Mediator of Cognitive Resilience to Alzheimer’s Disease
por: Hurst, Cheyenne, et al.
Publicado: (2023)

Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease
por: Higginbotham, Lenora, et al.
Publicado: (2020)

Effects of APOE Genotype on Brain Proteomic Network and Cell Type Changes in Alzheimer's Disease
por: Dai, Jingting, et al.
Publicado: (2018)

Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome
por: Dammer, Eric B., et al.
Publicado: (2022)

Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease
por: Johnson, Erik C. B., et al.
Publicado: (2018)

Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer’s disease
por: Modeste, Erica S., et al.
Publicado: (2023)

Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease
por: Donovan, Laura E, et al.
Publicado: (2013)

Correction to: Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer’s disease
por: Donovan, Laura E., et al.
Publicado: (2021)

Network Analysis of a Membrane-Enriched Brain Proteome across Stages of Alzheimer’s Disease
por: Higginbotham, Lenora, et al.
Publicado: (2019)

Quantitative proteomics of acutely-isolated mouse microglia identifies novel immune Alzheimer’s disease-related proteins
por: Rangaraju, Srikant, et al.
Publicado: (2018)

Quantitative proteomic analysis of the lysine acetylome reveals diverse SIRT2 substrates
por: Zhang, Hui, et al.
Publicado: (2022)

Identification of Conserved Proteomic Networks in Neurodegenerative Dementia
por: Swarup, Vivek, et al.
Publicado: (2020)

Phosphorylation regulates arginine-rich RNA-binding protein solubility and oligomerization
por: Kundinger, Sean R., et al.
Publicado: (2021)

Genetic background modifies CNS‐mediated sensorimotor decline in the AD‐BXD mouse model of genetic diversity in Alzheimer's disease
por: O'Connell, Kristen M. S., et al.
Publicado: (2019)

Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease
por: Zhou, Maotian, et al.
Publicado: (2020)

Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer’s Disease
por: Watson, Caroline M., et al.
Publicado: (2023)

Insights into the changes in the proteome of Alzheimer disease elucidated by a meta-analysis
por: Haytural, Hazal, et al.
Publicado: (2021)

Network analysis of the progranulin-deficient mouse brain proteome reveals pathogenic mechanisms shared in human frontotemporal dementia caused by GRN mutations
por: Huang, Meixiang, et al.
Publicado: (2020)

ER stress is not elevated in the 5XFAD mouse model of Alzheimer's disease
por: Sadleir, Katherine R., et al.
Publicado: (2018)

Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain
por: Wingo, Aliza P., et al.
Publicado: (2020)

Global quantitative analysis of the human brain proteome in Alzheimer’s and Parkinson’s Disease
por: Ping, Lingyan, et al.
Publicado: (2018)

Biochemical isolation of myonuclei employed to define changes to the myonuclear proteome that occur with aging
por: Cutler, Alicia A., et al.
Publicado: (2017)

Longitudinal Analysis of the Microbiome and Metabolome in the 5xfAD Mouse Model of Alzheimer’s Disease
por: Dunham, Sage J. B., et al.
Publicado: (2022)

Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer’s disease
por: Rayaprolu, Sruti, et al.
Publicado: (2020)

Phloroglucinol Attenuates the Cognitive Deficits of the 5XFAD Mouse Model of Alzheimer’s Disease
por: Yang, Eun-Jeong, et al.
Publicado: (2015)

Synaptosomal Mitochondrial Dysfunction in 5xFAD Mouse Model of Alzheimer's Disease
por: Wang, Lu, et al.
Publicado: (2016)

Axonal and myelinic pathology in 5xFAD Alzheimer’s mouse spinal cord
por: Chu, Tak-Ho, et al.
Publicado: (2017)

Retinal hyperspectral imaging in the 5xFAD mouse model of Alzheimer’s disease
por: Lim, Jeremiah K. H., et al.
Publicado: (2021)

Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer’s disease
por: Forner, Stefania, et al.
Publicado: (2021)

Therapeutic Effects of Aripiprazole in the 5xFAD Alzheimer’s Disease Mouse Model
por: Jeong, Ye Ji, et al.
Publicado: (2021)

Proteomics of protein post-translational modifications implicated in neurodegeneration
por: Ren, Ru-Jing, et al.
Publicado: (2014)

Proteomic Network Analysis of Alzheimer’s Disease Cerebrospinal Fluid Reveals Alterations Associated with APOE ε4 Genotype and Atomoxetine Treatment
por: Dammer, Eric B., et al.
Publicado: (2023)

Cortical cerebrovascular and metabolic perturbations in the 5xFAD mouse model of Alzheimer’s disease
por: Jullienne, Amandine, et al.
Publicado: (2023)

Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer’s disease
por: Ping, Lingyan, et al.
Publicado: (2020)

A proteomic network approach across the ALS‐FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain
por: Umoh, Mfon E, et al.
Publicado: (2017)

Lowering hippocampal miR-29a expression slows cognitive decline and reduces beta-amyloid deposition in 5xFAD mice
por: Mei, Zhen, et al.
Publicado: (2023)

Brain Cell Type-Specific Nuclear Proteomics Is Imperative to Resolve Neurodegenerative Disease Mechanisms
por: Nelson, Ruth S., et al.
Publicado: (2022)

A proteomic network approach resolves stage-specific molecular phenotypes in chronic traumatic encephalopathy
por: Gutierrez-Quiceno, Laura, et al.
Publicado: (2021)

No difference in cerebral perfusion between the wild-type and the 5XFAD mouse model of Alzheimer’s disease
por: DeBay, Drew R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gkvc0mq4e96gffd2c8dg9edj80